JAMES HART: Open Payments
NPI 1215915871 · FRANKLIN, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,005 in 75 payments from 13 companies in 2025. Trend: 2023 $17,815 · 2024 $14,160 · 2025 $10,005
Speaker / faculty: $8,371Food & beverage: $1,406Education: $117Travel & lodging: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $8,781 |
| Vanda Pharmaceuticals Inc. | 10 | $281 |
| E.R. Squibb & Sons, L.L.C. | 9 | $229 |
| Neurocrine BioSciences, Inc. | 8 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $149 |
| Janssen Pharmaceuticals, Inc | 9 | $146 |
| Alkermes, Inc. | 5 | $92 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| Luye Pharma (USA) Ltd. | 1 | $28 |
| Lundbeck LLC | 1 | $26 |
Products named: UZEDY, COBENFY, FANAPT, INGREZZA, CAPLYTA, INVEGA SUSTENNA, AUSTEDO XR, ARISTADA.
Industry payments across TN — which companies pay providers there.
